Måndag 8 Juni | 13:27:09 Europe / Stockholm

Bifogade filer

2026-06-08 11:36:00

8.6.2026 11:35:58 CEST | Ambu A/S | Changes in company's own shares

On 6 May 2026, Ambu announced a share buyback program (company announcement no. 12 2025/26). The share buyback program is carried out in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) (as amended) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016, also referred to as the Safe Harbor Regulations.                                                                                        

During the program, Ambu will repurchase shares for a total amount of up to DKK 300m from 6 May 2026 until no later than 30 September 2026. The repurchased shares are bought with the aim of completing a share capital decrease as set out in Article 5(2)(a) in MAR.

The following transactions have been made under the program from 01 Jun 2026 to 05 Jun 2026:

 

Number of shares

Average purchase price, DKK

Transaction value, DKK

Accumulated under the program after last announcement

838,614

63.7502

53,461,783

2026.06.01

125,000

65.6615

8,207,687

2026.06.02

45,000

65.2262

2,935,178

2026.06.03

45,000

64.0428

2,881,926

2026.06.04

6,000

64.7533

388,520

2026.06.05

0

0.0000

0

Accumulated under the program

1,059,614

64.0564

67,875,094

 

After the above disclosed transactions DKK 232,124,906 remains to be repurchased. Ambu now owns 5,209,225 treasury shares, corresponding to 1.9% of the share capital.

Contacts

  • Frederik Futtrup, Associate, Investor Relations, +45 6070 9526, frfu@ambu.com
  • Tine Bjørn Schmidt, Director of Corporate Communications, +45 2264 0697, tisc@ambu.com

About Ambu A/S

Ever since 1937, Ambu has surpassed expectations with groundbreaking solutions that improve patient care. Millions of patients, clinicians, and health systems worldwide rely on our endoscopy, anesthesia, and patient monitoring solutions for efficiency, safety, and performance. Our ownership of every stage of the product life cycle enables us to work closely with healthcare professionals, maintain a reliable product supply, and uphold full transparency. At our headquarters in Copenhagen, Denmark, and around the world in Europe, North America, and the Asia Pacific, 5,200+ Ambu team members are committed to delivering above and beyond.

Attachments